Benzylpenicillin novocaine (Powder) Instructions for Use
Marketing Authorization Holder
Sintez PJSC (Russia)
ATC Code
J01CE09 (Benzylpenicillin procaine)
Active Substance
Procaine benzylpenicillin
Dosage Form
| Benzylpenicillin novocaine | Powder for suspension for intramuscular administration 600,000 IU: vial 1 or 10 pcs. |
Dosage Form, Packaging, and Composition
Powder for preparation of suspension for intramuscular administration white in color, prone to clumping.
| 1 vial | |
| Procaine benzylpenicillin* | 600000 IU |
* benzylpenicillin procaine (benzylpenicillin novocaine salt).
Colorless glass vials (1) – cardboard packs.
Colorless glass vials (10) – cardboard packs.
Clinical-Pharmacological Group
Penicillin antibiotic, destroyed by penicillinase
Pharmacotherapeutic Group
Systemic antibacterial agents; beta-lactam antibacterial agents, penicillins; beta-lactamase sensitive penicillins
Pharmacological Action
Bactericidal antibiotic from the group of biosynthetic penicillins. It suppresses the synthesis of the cell wall of microorganisms.
Active against gram-positive bacteria Staphylococcus spp., Streptococcus spp. (including Streptococcus pneumoniae), Corynebacterium diphtheriae, Bacillus anthracis; gram-negative bacteria: Neisseria gonorrhoeae, Neisseria meningitidis; anaerobic spore-forming rods; as well as Actinomyces spp., Spirochaetaceae.
It is not active against most gram-negative bacteria, rickettsiae, viruses, protozoa. Strains of microorganisms that produce penicillinase are resistant to the action of procaine benzylpenicillin. It is destroyed in an acidic environment.
The procaine salt of benzylpenicillin is characterized by a longer duration of action compared to the potassium and sodium salts.
Pharmacokinetics
After intramuscular administration, Tmax is 20-30 min. T1/2 is 30-60 min, in renal failure – 4-10 h or more. Plasma protein binding is 60%. It penetrates into organs, tissues and biological fluids, except for cerebrospinal fluid, eye tissue and prostate. It penetrates the blood-brain barrier when the meninges are inflamed. It is excreted by the kidneys unchanged.
Indications
Infectious and inflammatory diseases caused by susceptible pathogens: lobar and focal pneumonia, pleural empyema, bronchitis; sepsis, septic endocarditis (acute and subacute), peritonitis; meningitis; osteomyelitis; infections of the genitourinary system (pyelonephritis, pyelitis, cystitis, urethritis, gonorrhea, blennorrhea, syphilis, cervicitis), biliary tract (cholangitis, cholecystitis); wound infection, infections of the skin and soft tissues: erysipelas, impetigo, secondarily infected dermatoses; diphtheria; scarlet fever; anthrax; actinomycosis; ENT diseases, eye diseases.
ICD codes
| ICD-10 code | Indication |
| A22 | Anthrax |
| A36 | Diphtheria |
| A38 | Scarlet fever |
| A40 | Streptococcal sepsis |
| A41 | Other sepsis |
| A42 | Actinomycosis |
| A46 | Erysipelas |
| A51 | Early syphilis |
| A54 | Gonococcal infection |
| G00 | Bacterial meningitis, not elsewhere classified |
| H04.3 | Acute and unspecified inflammation of lacrimal passages |
| H04.4 | Chronic inflammation of lacrimal passages |
| H19.2 | Keratitis and keratoconjunctivitis in other infectious and parasitic diseases classified elsewhere |
| I33 | Acute and subacute endocarditis |
| J01 | Acute sinusitis |
| J02 | Acute pharyngitis |
| J03 | Acute tonsillitis |
| J04 | Acute laryngitis and tracheitis |
| J15 | Bacterial pneumonia, not elsewhere classified |
| J20 | Acute bronchitis |
| J32 | Chronic sinusitis |
| J35.0 | Chronic tonsillitis |
| J37 | Chronic laryngitis and laryngotracheitis |
| J42 | Unspecified chronic bronchitis |
| J86 | Pyothorax (pleural empyema) |
| K65.0 | Acute peritonitis (including abscess) |
| K81.0 | Acute cholecystitis |
| K81.1 | Chronic cholecystitis |
| K83.0 | Cholangitis |
| L01 | Impetigo |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L03 | Cellulitis |
| L08.0 | Pyoderma |
| L08.8 | Other specified local infections of skin and subcutaneous tissue |
| L30.3 | Infectious dermatitis (infectious eczema) |
| M86 | Osteomyelitis |
| N10 | Acute tubulointerstitial nephritis (acute pyelonephritis) |
| N11 | Chronic tubulointerstitial nephritis (chronic pyelonephritis) |
| N30 | Cystitis |
| N34 | Urethritis and urethral syndrome |
| N72 | Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis) |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| ICD-11 code | Indication |
| 1A61.Z | Early syphilis, unspecified |
| 1A7Z | Gonococcal infection, unspecified |
| 1B50 | Scarlet fever |
| 1B70.0Z | Erysipelas, unspecified |
| 1B70.1 | Streptococcal cellulitis of the skin |
| 1B70.2 | Staphylococcal cellulitis of the skin |
| 1B70.Z | Bacterial cellulitis or lymphangitis caused by unspecified bacterium |
| 1B72.0 | Bullous impetigo |
| 1B72.1 | Nonbullous impetigo |
| 1B72.Z | Impetigo, unspecified |
| 1B75.0 | Furuncle |
| 1B75.1 | Carbuncle |
| 1B75.2 | Furunculosis |
| 1B75.3 | Pyogenic skin abscess |
| 1B7Y | Other specified pyogenic bacterial infections of skin or subcutaneous tissue |
| 1B97 | Anthrax |
| 1C10.Z | Actinomycosis, unspecified |
| 1C17.Z | Diphtheria, unspecified |
| 1C44 | Non-pyogenic bacterial infections of skin |
| 1D01.0Z | Bacterial meningitis, unspecified |
| 1G40 | Sepsis without septic shock |
| 9A11.Z | Disorders of the lacrimal passages, unspecified |
| 9A1Z | Diseases of the lacrimal system, unspecified |
| 9A71 | Infectious keratitis |
| BB4Z | Acute or subacute endocarditis, unspecified |
| CA01 | Acute rhinosinusitis |
| CA02.Z | Acute pharyngitis, unspecified |
| CA03.Z | Acute tonsillitis, unspecified |
| CA05 | Acute laryngitis or tracheitis |
| CA0A.Z | Chronic rhinosinusitis, unspecified |
| CA0F.Y | Other specified chronic diseases of the palatine tonsils and adenoids |
| CA0G | Chronic laryngitis or laryngotracheitis |
| CA20.1Z | Chronic bronchitis, unspecified |
| CA40.0Z | Bacterial pneumonia, unspecified |
| CA42.Z | Acute bronchitis, unspecified |
| CA44 | Pyothorax |
| DC12.0Z | Acute cholecystitis, unspecified |
| DC12.1 | Chronic cholecystitis |
| DC13 | Cholangitis |
| DC50.0 | Primary peritonitis |
| DC50.2 | Peritoneal abscess |
| DC50.Z | Peritonitis, unspecified |
| EA50.3 | Staphylococcal scarlet fever |
| EA88.0Z | Infectious dermatitis, unspecified |
| EB21 | Pyoderma gangrenosum |
| FB84.Z | Osteomyelitis or osteitis, unspecified |
| GB50 | Acute tubulo-interstitial nephritis |
| GB51 | Acute pyelonephritis |
| GB55.Z | Chronic tubulo-interstitial nephritis, unspecified |
| GB5Z | Renal tubulo-interstitial diseases, unspecified |
| GC00.Z | Cystitis, unspecified |
| GC02.Z | Urethritis and urethral syndrome, unspecified |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
| GA0Z | Inflammatory diseases of female genital tract, unspecified |
| XA5WW1 | Cervix uteri |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
It is administered intramuscularly.
Intravenous and endolumbar administration is prohibited.
The average therapeutic dose for adults: single – 300,000 IU, daily – 600,000 IU. The maximum daily dose for adults is 1,200,000 IU.
For children under 1 year of age – 50,000-100,000 IU/kg/day, over 1 year – 50,000 IU/kg/day.
The frequency of administration is 1-2 times/day.
The duration of treatment, depending on the form and severity of the disease, ranges from 7-10 days to 2 months or more (septic endocarditis, sepsis).
Adverse Reactions
Allergic reactions hyperthermia, urticaria, skin rash, rash on mucous membranes, arthralgia, eosinophilia, angioedema, interstitial nephritis, bronchospasm; rarely – anaphylactic shock
Local reactions: pain and induration at the injection site.
If it enters the vascular bed tinnitus, visual impairment, fear, dizziness, short-term loss of consciousness.
When administered in high doses neurotoxic phenomena are possible – nausea, vomiting, increased reflex excitability, symptoms of meningism, convulsions, coma.
Contraindications
Hypersensitivity to the group of penicillins, allergy to procaine.
Use in Pregnancy and Lactation
Use with caution during pregnancy and during lactation (breastfeeding).
Use in Hepatic Impairment
The drug is approved for use in impaired liver function
Special Precautions
With caution: bronchial asthma, hay fever and other allergic diseases, decreased blood clotting activity, pregnancy, lactation period, renal failure.
If no effect is noted 2-3 days (maximum 5 days) after starting the drug, it is necessary to switch to the use of other antibiotics or combination therapy.
Due to the possibility of developing fungal lesions, it is advisable during long-term treatment with benzylpenicillin to prescribe B vitamins and vitamin C, and if necessary, nystatin and levorin.
It must be taken into account that the use of procaine benzylpenicillin in reduced doses or too early termination of treatment often leads to the emergence of resistant strains of pathogens.
When treating venereal diseases, if syphilis is suspected, before starting therapy and then for 4 months, it is necessary to conduct microscopic and serological studies.
If any allergic reaction occurs, immediate discontinuation of treatment is required.
Drug Interactions
Bactericidal antibiotics (including cephalosporins, vancomycin, rifampicin, aminoglycosides) act synergistically with procaine benzylpenicillin. Bacteriostatic antibiotics (including macrolides, chloramphenicol, lincosamides, tetracyclines) have an antagonistic effect.
It increases the effectiveness of indirect anticoagulants (by suppressing the intestinal microflora, it reduces the prothrombin index); reduces the effectiveness of oral contraceptives, drugs in the process of metabolism of which para-aminobenzoic acid is formed, ethinyl estradiol – the risk of developing breakthrough bleeding.
Diuretics, allopurinol, tubular secretion blockers, phenylbutazone, NSAIDs, by reducing tubular secretion, increase the concentration of benzylpenicillin.
Allopurinol increases the risk of allergic reactions (skin rash).
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer